Description
UWA-101 (hydrochloride) is an analytical reference material that is structurally categorized as an amphetamine. It inhibits both serotonin and dopamine reuptake (K
is = 467 and 894 nM, respectively), but has no effect on the reuptake of noradrenaline (K
i > 50,000 nM).
1 UWA-101 enhances L-DOPA anti-parkinsonian action without exacerbating dyskinesia.
2 This product is intended for research and forensic applications.
Uses
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC50 values of 3.6 μM and 2.3 μM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease[1][2].
References
1. Johnston, T.H., Millar, Z., Huot, P., et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates FASEB J. 26(5),2154-2163(2012).
2. Huot, P., Johnston, T.H., Gandy, M.N., et al. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset PLoS One 7(9),(2012).
